Pancreas (Endocrine)

Protocol applies to all endocrine tumors of the pancreas.

Protocol revision date: January 2005
No AJCC/UICC staging system

Procedures
- Incisional Biopsy (No Accompanying Checklist)
- Excisional Biopsy (Enucleation)
- Partial Pancreatectomy
- Pancreaticoduodenectomy (Whipple Resection)

Author
Carolyn C. Compton, MD, PhD
Department of Pathology, McGill University, Montreal, Quebec, Canada
For the Members of the Cancer Committee, College of American Pathologists
© 2005. College of American Pathologists. All rights reserved. 
The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.
Summary of Changes to Checklist(s)

Protocol revision date: January 2005

The following changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

Protocol in General

Tumors with mixed endocrine and acinar cell differentiation are no longer included in this protocol (see Exocrine Pancreas protocol).

Excisional Biopsy (Enucleation), Resection Checklist

Macroscopic

Specimen Type: Excisional biopsy (enucleation) was added, as shown below

<table>
<thead>
<tr>
<th>Specimen Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>___ Excisional biopsy (enucleation)</td>
</tr>
<tr>
<td>___ Pancreaticoduodenectomy (Whipple resection), partial pancreatectomy</td>
</tr>
<tr>
<td>___ Pancreaticoduodenectomy (Whipple resection), total pancreatectomy</td>
</tr>
<tr>
<td>___ Pylorus sparing pancreaticoduodenectomy, partial pancreatectomy</td>
</tr>
<tr>
<td>___ Pylorus sparing pancreaticoduodenectomy, total pancreatectomy</td>
</tr>
<tr>
<td>___ Partial resection, pancreatic body</td>
</tr>
<tr>
<td>___ Partial resection, pancreatic tail</td>
</tr>
<tr>
<td>___ Other (specify): ____________________________</td>
</tr>
<tr>
<td>___ Not specified</td>
</tr>
</tbody>
</table>
Surgical Pathology Cancer Case Summary (Checklist)

Protocol revision date: January 2005
Applies to endocrine tumors only
No AJCC/UICC staging system

PANCREAS (ENDOCRINE): Excisional Biopsy (Enucleation), Resection

Patient name:
Surgical pathology number:

Note: Check 1 response unless otherwise indicated.

MACROSCOPIC

Specimen Type
___ Excisional biopsy (enucleation)
___ Pancreaticoduodenectomy (Whipple resection), partial pancreatectomy
___ Pancreaticoduodenectomy (Whipple resection), total pancreatectomy
___ Pylorus sparing pancreaticoduodenectomy, partial pancreatectomy
___ Pylorus sparing pancreaticoduodenectomy, total pancreatectomy
___ Partial resection, pancreatic body
___ Partial resection, pancreatic tail
___ Other (specify): ____________________________
___ Not specified

*Tumor Site (check all that apply)
*___ Pancreatic head
*___ Uncinate process
*___ Pancreatic body
*___ Pancreatic tail
*___ Indeterminate
*___ Not specified

Tumor Focality
___ Unifocal
___ Multifocal

*Tumor Configuration (check all that apply)
*___ Infiltrative
*___ Circumscribed
    *___ Solid, entirely encapsulated
    *___ Solid, partially encapsulated
    *___ Cystic, entirely encapsulated
    *___ Cystic, partially encapsulated

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Tumor Size
Greatest dimension: ___ cm
*Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)

*Other OrgansSubmitted (check all that apply)
*___ None
*___ Spleen
*___ Gallbladder
*___ Other(s) (specify): ____________________________

MICROSCOPIC

*Functional Type
*___ Cannot be assessed
*___ Pancreatic endocrine tumor, functional
  (correlation with clinical syndrome and/or elevated serum levels of hormone product) (specify type): ____________________________
*___ Pancreatic endocrine tumor, nonsecretory
*___ Pancreatic endocrine tumor, secretory status unknown

Extent of Invasion

Primary Tumor
___ Tumor limited to pancreas
___ Tumor invades beyond pancreatic capsule, but does not invade adjacent structures/organs
___ Tumor invades adjacent structures/organs (check all that apply):
   ___ Duodenum
   ___ Bile duct
   ___ Stomach
   ___ Spleen
   ___ Colon
   ___ Adjacent large vessels (eg, portal vein, celiac artery, superior mesenteric vessels, common hepatic vessels)
   ___ Other (specify): ____________________________

Regional Lymph Nodes
___ Cannot be assessed
___ No regional lymph node metastasis
___ Regional lymph node metastasis
Specify: Number examined: _____
Number involved: _____

Distant Metastasis
___ Cannot be assessed
___ Distant metastasis
   *Specify site(s) if known: ____________________________

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.
Margins (check all that apply)
___ Cannot be assessed
___ Uninvolved by tumor
          *Distance of tumor from closest margin: ___ mm
          *Specify margin (if possible): ____________________________
___ Margin(s) involved by invasive carcinoma
          ___ Posterior retroperitoneal (radial) margin: posterior surface of pancreas
          ___ Uncinate process margin (non-peritonealized surface of the
              uncinate process)
          ___ Distal pancreatic margin
          ___ Common bile duct margin
          ___ Proximal pancreatic margin
          ___ Other (specify): ____________________________

*Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)
*___ Absent
*___ Present
*___ Indeterminate

*Perineural Invasion
*___ Absent
*___ Present

*Mitotic Activity
*___ Not applicable
*___ Absent
*___ Present; less than or equal to 4 mitoses/10 high-power fields
*___ Present; greater than 4 mitoses/10 high-power fields

*Additional Pathologic Findings (check all that apply)
*___ None identified
*___ Chronic pancreatitis
*___ Acute pancreatitis
*___ Adenomatosis
*___ Other (specify): ____________________________

*Comment(s)

* Data elements with asterisks are not required for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.